Market Cap 3.13B
Revenue (ttm) 233.18M
Net Income (ttm) -321.55M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -137.90%
Debt to Equity Ratio 0.00
Volume 1,573,700
Avg Vol 1,860,078
Day's Range N/A - N/A
Shares Out 89.47M
Stochastic %K 38%
Beta 0.89
Analysts Strong Sell
Price Target $41.14

Company Profile

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport di...

Industry: Biotechnology
Sector: Healthcare
Phone: 888 969 7879
Address:
3611 Valley Centre Drive, Suite 300, San Diego, United States
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 6 at 3:33 AM
Actionable Trade Alert for $TVTX: Market Context: $TVTX is currently trading at $35.33, showing bullish momentum as reflected by an RSI of 58.37, indicating it is not overbought. The stock is above its 30-day MA of $33.77 and 50-day MA of $30.62, suggesting a positive trend. Directional Bias: The stock's recent performance, with a 60-day high of $37.5, indicates potential for upward movement. The RSI supports this bullish outlook, as it is approaching the neutral zone without being overbought. Trade Plan: - Suggested Entry: $35.50 - Stop Loss: $33.00 (approx. 7% below entry) - Take Profit Targets: 1. $37.00 (4.2% ROI) 2. $38.00 (7.9% ROI) 3. $41.50 (17.9% ROI) This plan provides a solid risk-reward ratio, with the potential for a significant return on the third target. Monitor the stock closely for any changes in momentum. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 5 at 11:08 PM
Actionable Trade Alert for $TVTX: Market Context: $TVTX is currently trading at $35.33, showing bullish momentum as reflected by an RSI of 58.37, indicating it is not overbought. The stock is above its 30-day MA of $33.77 and 50-day MA of $30.62, suggesting a positive trend. Directional Bias: The stock's recent performance, with a 60-day high of $37.5, indicates potential for upward movement. The RSI supports this bullish outlook, as it is approaching the neutral zone without being overbought. Trade Plan: - Suggested Entry: $35.50 - Stop Loss: $33.00 (approx. 7% below entry) - Take Profit Targets: 1. $37.00 (4.2% ROI) 2. $38.00 (7.9% ROI) 3. $41.50 (17.9% ROI) This plan provides a solid risk-reward ratio, with the potential for a significant return on the third target. Monitor the stock closely for any changes in momentum. https://privateprofiteers.com
0 · Reply
Quantumup
Quantumup Dec. 5 at 3:09 PM
TD Cowen⬆️the PT on $VERA to $73 from $60 and reiterated at a Buy rating. $TVTX $OTSKY $JBIO $VRTX ABBV ALNY IONS Here's what TD Cowen had to say: We are increasing our estimated gross annual pricing for ataci' in IgAN to $350K based on new comparator product pricing, increasing our PT to $73 based on higher peak US sales of $1.64B in 2033. Mgmt said Ph2 ataci' PIONEER IgAN/pMN/FSGS-data may come in 1Q26. VERA may pursue a monthly sNDA path as the formulation is the same as weekly. A June/July PDUFA is likely for weekly dosing in IgAN.
0 · Reply
Meigs1865
Meigs1865 Dec. 4 at 9:52 PM
$TVTX IBD has this stock with a 98 composite rating, also ranked on the IBD 50. The composite rating means it is outperforming 98% of the stocks on the market. Last ER was off the charts on EPS and Revenue, expected at -0.17, came in at 0.29. Huge.
0 · Reply
JFais
JFais Dec. 4 at 9:07 PM
$TVTX- every time someone asks me about this one (previous trade chart)🤦‍♂️
0 · Reply
Starbound28
Starbound28 Dec. 4 at 12:45 PM
0 · Reply
Quantumup
Quantumup Dec. 2 at 9:12 PM
Raymond James reiterated $VERA Strong Buy/$73 after pricing data for atacicept's competitor ( $OTSKY ) in the IgAN space, sibeprenlimab (Voyxact), was been disclosed. $OTSKY $TVTX $JBIO $VRTX ABBV ALNY IONS Here's what Raymond James had to say in its note: https://x.com/Quantumup1/status/1995963371083186594?s=20
0 · Reply
HamBoneXoXo
HamBoneXoXo Dec. 1 at 5:45 AM
$CAPR A bit strange noting the name deramiocel for alport syndrome being advanced by Travere Therapeutics $TVTX. What is that all about? Anyone? My guess this is an error in the report.
1 · Reply
Nyman189
Nyman189 Nov. 30 at 11:26 PM
$TVTX 50$ next year
0 · Reply
Nyman189
Nyman189 Nov. 30 at 11:25 PM
0 · Reply
Latest News on TVTX
3 Potential Mid-Cap Biotech Buyout Targets In 2026

Dec 3, 2025, 6:22 PM EST - 3 days ago

3 Potential Mid-Cap Biotech Buyout Targets In 2026

COGT IBB XBI CYTK


3 Potential Biotech Acquisition Targets

Sep 19, 2025, 12:53 PM EDT - 2 months ago

3 Potential Biotech Acquisition Targets

AZN ETNB INCY MLYS SNDX


Travere Therapeutics: Compelling FILSPARI Growth Is Hard To Ignore

Aug 12, 2025, 12:15 PM EDT - 4 months ago

Travere Therapeutics: Compelling FILSPARI Growth Is Hard To Ignore


PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 6 at 3:33 AM
Actionable Trade Alert for $TVTX: Market Context: $TVTX is currently trading at $35.33, showing bullish momentum as reflected by an RSI of 58.37, indicating it is not overbought. The stock is above its 30-day MA of $33.77 and 50-day MA of $30.62, suggesting a positive trend. Directional Bias: The stock's recent performance, with a 60-day high of $37.5, indicates potential for upward movement. The RSI supports this bullish outlook, as it is approaching the neutral zone without being overbought. Trade Plan: - Suggested Entry: $35.50 - Stop Loss: $33.00 (approx. 7% below entry) - Take Profit Targets: 1. $37.00 (4.2% ROI) 2. $38.00 (7.9% ROI) 3. $41.50 (17.9% ROI) This plan provides a solid risk-reward ratio, with the potential for a significant return on the third target. Monitor the stock closely for any changes in momentum. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 5 at 11:08 PM
Actionable Trade Alert for $TVTX: Market Context: $TVTX is currently trading at $35.33, showing bullish momentum as reflected by an RSI of 58.37, indicating it is not overbought. The stock is above its 30-day MA of $33.77 and 50-day MA of $30.62, suggesting a positive trend. Directional Bias: The stock's recent performance, with a 60-day high of $37.5, indicates potential for upward movement. The RSI supports this bullish outlook, as it is approaching the neutral zone without being overbought. Trade Plan: - Suggested Entry: $35.50 - Stop Loss: $33.00 (approx. 7% below entry) - Take Profit Targets: 1. $37.00 (4.2% ROI) 2. $38.00 (7.9% ROI) 3. $41.50 (17.9% ROI) This plan provides a solid risk-reward ratio, with the potential for a significant return on the third target. Monitor the stock closely for any changes in momentum. https://privateprofiteers.com
0 · Reply
Quantumup
Quantumup Dec. 5 at 3:09 PM
TD Cowen⬆️the PT on $VERA to $73 from $60 and reiterated at a Buy rating. $TVTX $OTSKY $JBIO $VRTX ABBV ALNY IONS Here's what TD Cowen had to say: We are increasing our estimated gross annual pricing for ataci' in IgAN to $350K based on new comparator product pricing, increasing our PT to $73 based on higher peak US sales of $1.64B in 2033. Mgmt said Ph2 ataci' PIONEER IgAN/pMN/FSGS-data may come in 1Q26. VERA may pursue a monthly sNDA path as the formulation is the same as weekly. A June/July PDUFA is likely for weekly dosing in IgAN.
0 · Reply
Meigs1865
Meigs1865 Dec. 4 at 9:52 PM
$TVTX IBD has this stock with a 98 composite rating, also ranked on the IBD 50. The composite rating means it is outperforming 98% of the stocks on the market. Last ER was off the charts on EPS and Revenue, expected at -0.17, came in at 0.29. Huge.
0 · Reply
JFais
JFais Dec. 4 at 9:07 PM
$TVTX- every time someone asks me about this one (previous trade chart)🤦‍♂️
0 · Reply
Starbound28
Starbound28 Dec. 4 at 12:45 PM
0 · Reply
Quantumup
Quantumup Dec. 2 at 9:12 PM
Raymond James reiterated $VERA Strong Buy/$73 after pricing data for atacicept's competitor ( $OTSKY ) in the IgAN space, sibeprenlimab (Voyxact), was been disclosed. $OTSKY $TVTX $JBIO $VRTX ABBV ALNY IONS Here's what Raymond James had to say in its note: https://x.com/Quantumup1/status/1995963371083186594?s=20
0 · Reply
HamBoneXoXo
HamBoneXoXo Dec. 1 at 5:45 AM
$CAPR A bit strange noting the name deramiocel for alport syndrome being advanced by Travere Therapeutics $TVTX. What is that all about? Anyone? My guess this is an error in the report.
1 · Reply
Nyman189
Nyman189 Nov. 30 at 11:26 PM
$TVTX 50$ next year
0 · Reply
Nyman189
Nyman189 Nov. 30 at 11:25 PM
0 · Reply
RunnerSignals
RunnerSignals Nov. 28 at 7:45 PM
$PFE $SNY $TVTX $TXN $WMB upgraded and ready to roll and showing strength! https://stocksrunner.com/news/2025-11-28-stock-upgrades-today-highlight-top-picks-with-strong-near-term-upside
0 · Reply
Quantumup
Quantumup Nov. 28 at 12:17 PM
H.C. Wainwright reiterated $VERA Buy-$90 and said—On November 25, the FDA granted accelerated approval (AA) to sibeprenlimab, marketed as Voyxact by Otsuka ( $OTSKY; not rated), for the treatment of adults with primary immunoglobulin A nephropathy (IgAN). $TVTX $NVS JBIO VRTX ABBV ALNY IONS H.C. Wainwright went on to say:
0 · Reply
JarvisFlow
JarvisFlow Nov. 28 at 11:57 AM
HC Wainwright & Co. has updated their rating for Travere Therapeutics ( $TVTX ) to Buy with a price target of 47.
0 · Reply
DeadInvestor
DeadInvestor Nov. 27 at 4:45 PM
$TVTX Renalys Pharma announces positive top line results in IgA phase III study in Japan. https://renalys.com/renalys-pharma-announces-positive-topline-results-from-phase-iii-study-of-sparsentan-in-japanese-patients-with-iga-nephropathy/
0 · Reply
MichaelKTrades
MichaelKTrades Nov. 25 at 9:44 PM
Biotech- Health care theme is still hot, most of my current ideas picked up here. $ROIV $TVTX- big accumulation, bull flag higher lows supported by the 10D MA
1 · Reply
Quantumup
Quantumup Nov. 25 at 11:57 AM
Clear Street🏁 $JBIO Buy/$25 $OTSKY $TVTX $NVS $VRTX IONS AZN CALT Clear Street said in its initiation report:
0 · Reply
ivanhoff
ivanhoff Nov. 24 at 5:23 PM
$TVTX - another biotech setting up near its multi-year highs.
1 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Nov. 23 at 10:47 PM
Attached is a table that documents certain valuation related data points of a pool of newer commercial-stage non-oncology focused bios (those with 1st approvals since 1/1/2020). The table includes a handful of older such bios. We're interested in the 5 on the bottom. Genuine responses would be appreciated on; $BCRX For those investors that believe some commercial-stage bios trade in cycles, is BCRX near a bottom? $TVTX has more than doubled the last 6 month yet still trades at meaningfully lower multiples than peers. $LGND multiples are "off-the-charts" but investors often cite low forecasts from future royalties including TVTX $FOLD Are there any updates on the generic? $APLS ? This is not investment advice. We're genuinely curious as our club has a major re-balance at year end (we plan for now).
3 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 23 at 9:08 PM
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Nov. 19 at 2:50 AM
The attachment lists M&A valuation profiles of 2 pools of commercial-stage biopharmas. Note the valuations paid and 10-year revenue forecasts are provided sourced from the acquiree's 14A or 14D9 filing The first are those whose product is forecast to get to $750MM to $1.0B in product sales by year 10 from M&A. Commercial-stage bios with this profile are generally acquired for $1.7 to $2.1B (excluding CVRs). The second pool are those whose product is forecast to get to roughly $1.5 to $2.0B by year 10 from M&A. These bios are generally acquired for $3 to $5B (approximately). Note virtually all bios in both pools are acquired for 0.30 to 0.40X cumulative 10-year revenue forecasts. If we had to guess which commercial-stage non-oncology focused bios are next to be acquired...again our guesses would be; $TARS $MIRM $TVTX (second group) $FOLD (once patent issue is behind them) $ARWR ONCOLOGY: SNDX URGN @This_Bull_Is_Retired
1 · Reply
Meigs1865
Meigs1865 Nov. 18 at 4:53 PM
$TVTX appears to be safe harbor while the market has been down the last two days, TVTX keeps in the green.
0 · Reply
Ruffy__
Ruffy__ Nov. 18 at 8:52 AM
$TVTX True gem
0 · Reply